Government of India will review the FDI policy in the pharmaceutical sector in the wake of concerns over multinationals taking over domestic drug makers. The Department of Industrial Policy and Promotion (DIPP) has proposed to reduce FDI cap from 100 per cent to 49 per cent in the “rare or critical pharmaverticals.”It has also proposed to incorporate conditions for foreign firms like mandatory investment in R&D and non-compete clause in the shareholders pact.